ISB News

New Study on How Microbes Learn to Predict the Future

Adaptive Prediction of Yeast

July 28, 2017

In a study published in Genome Biology and Evolution, researchers at Institute for Systems Biology (ISB) designed an experiment to evolve novel adaptive prediction capability in yeast by repetitively exposing it to caffeine, followed by a toxin. Remarkably, the yeast cells learned the structure of this novel environmental pattern within as few as 50 generations to use caffeine as a cue for anticipating and mitigating lethal effects of the toxin.

3 Bullets:

  • Like plants and animals, even microbes can anticipate and prepare in advance for future changes in their environment
  • Similar to how Pavlov trained a dog to anticipate food when it heard a bell, ISB researchers trained yeast to anticipate a lethal toxin when it sensed caffeine
  • The study revealed how in a very short period of time yeast can evolve to ‘learn’ and ‘predict’ new patterns in their environment

Read More

Recent Articles

  • 2024 Year in Review

    Reflecting on the past year, ISB has a lot to celebrate: groundbreaking research published in leading scientific journals, well-earned promotions, widespread media coverage, and more. Enjoy our year-in-review roundup highlighting some of the important, interesting, and impactful highlights of 2024.

  • My Digital Gut

    ISB Named Winner of 2024-2025 Amazon Web Services IMAGINE Grant for Nonprofits

    ISB has been selected as a winner of the 2024 Amazon Web Services (AWS) IMAGINE Grant. The grant will support ISB’s continued development of My Digital Gut, an online decision-support platform that will help make microbiome-informed nutrition and healthcare personalized, predictive, and preventive. 

  • ISB-Developed MetaboCore Offers Precision Cancer Care Faster Than Ever 

    ISB Associate Professor Dr. Wei Wei and his colleagues have developed a promising new companion diagnostic tool called MetaboCore to help physicians quickly select the most effective systemic therapy for each cancer patient.